Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genmab A/S (GMAB)

Genmab A/S (GMAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,833,700
  • Shares Outstanding, K 128,746
  • Annual Sales, $ 479,180 K
  • Annual Income, $ 233,190 K
  • 60-Month Beta N/A
  • Price/Sales 5.95
  • Price/Cash Flow N/A
  • Price/Book 1.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.36
  • Number of Estimates 3
  • High Estimate 0.42
  • Low Estimate 0.33
  • Prior Year 2.13
  • Growth Rate Est. (year over year) -83.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.70 +13.07%
on 10/14/19
22.35 -0.31%
on 11/13/19
+2.80 (+14.37%)
since 10/11/19
3-Month
18.80 +18.51%
on 10/02/19
22.35 -0.31%
on 11/13/19
+2.38 (+11.96%)
since 08/13/19
52-Week
13.64 +63.40%
on 11/15/18
22.35 -0.31%
on 11/13/19
+8.20 (+58.24%)
since 11/13/18

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade GMAB with:

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

2nd Resistance Point 22.45
1st Resistance Point 22.37
Last Price 22.28
1st Support Level 22.18
2nd Support Level 22.07

See More

52-Week High 22.35
Last Price 22.28
Fibonacci 61.8% 19.02
Fibonacci 50% 17.99
Fibonacci 38.2% 16.96
52-Week Low 13.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar